<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CAC1C7CD-C8D4-4F19-9E6A-1DEC5FA8D21F"><gtr:id>CAC1C7CD-C8D4-4F19-9E6A-1DEC5FA8D21F</gtr:id><gtr:name>Dr. Reddy's Laboratories</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Life Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CAC1C7CD-C8D4-4F19-9E6A-1DEC5FA8D21F"><gtr:id>CAC1C7CD-C8D4-4F19-9E6A-1DEC5FA8D21F</gtr:id><gtr:name>Dr. Reddy's Laboratories</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/ABE053F5-18EB-4A82-AC8A-1C8B0D4FEDFE"><gtr:id>ABE053F5-18EB-4A82-AC8A-1C8B0D4FEDFE</gtr:id><gtr:firstName>Nick</gtr:firstName><gtr:surname>Goddard</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6E67417F-B80E-4C95-BF96-FB92B017EF03"><gtr:id>6E67417F-B80E-4C95-BF96-FB92B017EF03</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Michael</gtr:otherNames><gtr:surname>Gardiner</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/731AE06C-1C1E-47C3-AB6A-145D0EF81036"><gtr:id>731AE06C-1C1E-47C3-AB6A-145D0EF81036</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Munro</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/855ACD43-8240-48FB-AF40-C8F87B294B74"><gtr:id>855ACD43-8240-48FB-AF40-C8F87B294B74</gtr:id><gtr:firstName>Nigel</gtr:firstName><gtr:otherNames>Shaun</gtr:otherNames><gtr:surname>Scrutton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CA1A69B3-DF20-4897-B704-CB20D8B70228"><gtr:id>CA1A69B3-DF20-4897-B704-CB20D8B70228</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>Robert</gtr:otherNames><gtr:surname>Fielden</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5C7FF154-503B-4CD0-AD2B-A4E833331D55"><gtr:id>5C7FF154-503B-4CD0-AD2B-A4E833331D55</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Leys</gtr:surname><gtr:orcidId>0000-0003-4845-8443</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D5488AA4-57C7-4C4B-82D2-8DFFC459C522"><gtr:id>D5488AA4-57C7-4C4B-82D2-8DFFC459C522</gtr:id><gtr:firstName>Gillian</gtr:firstName><gtr:surname>Stephens</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FE010717%2F1"><gtr:id>2310884A-3201-4D79-A918-81543ABA8E22</gtr:id><gtr:title>A generic biocatalytic reaction platform for the stereospecific reduction and oxidation of alkenes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/E010717/1</gtr:grantReference><gtr:abstractText>We propose an ambitious, interdisciplinary research programme to develop a viable manufacturing process, independent of redox coenzymes, to exploit a wide range of novel and industrially relevant redox biotransformations. Our approach is based on the development of (i) microfabricated electrode systems and arrayed microfluidic reactors, (ii) specifically tailored and robust redox catalysts and (iii) the integration and process optimisation of 'engineered catalysts' within the microreactor environment, incorporating on-line quantification of reaction products and facile removal of the desired product by microfluidic liquid-liquid extraction. The technology platform is designed to accommodate a wide range of redox biocatalysts by employing generic methods of electron delivery, and to by-pass the requirement for coenzyme recycling/regeneration. The outcome will be a viable manufacturing process for the production and rapid recovery of high valuable enantiomeric products for the pharmaceutical and synthetic chemistry communities. For the first time, our programme will drive the diverse catalytic potential of redox enzymes towards industrial exploitation, and will thus make a substantial contribution to the field of biocatalysis. The proposed programme is highly innovative and provides generic solutions to the key problems associated with the exploitation of redox enzymes in industrial biocatalytic processes. The programme capitalises on the unique combination of expertise available within the UK Centre of Excellence in Biocatalysis, Bioprocessing and Biomanufacturing (CoEBio3) at the University of Manchester and the excellent research infrastructure available to this group of research workers in the Manchester Interdisciplinary Biocentre. This direct involvement of the 13 member companies of CoEBio3 will provide an invaluable route for effective dissemination and implementation of the project findings.</gtr:abstractText><gtr:technicalSummary>Redox biotransformations should provide many new, versatile routes to manufacture both chiral and non-chiral speciality chemicals. In practice, it is extremely difficult to operate these reactions economically at scale, since the reactions depend on the provision of stoichiometric quantities of NAD(P)H. Since the cofactors are extremely expensive, economic viability depends on recycling the cofactors. In vitro cofactor recycling using coupled enzymes is generally impractical at large scale (although there are a few exceptions), and alternative approaches, such as artificial cofactors or chemical, electrochemical or photochemical reduction of cofactors, are not industrially viable. As a result, nearly all redox biotransformations are operated using whole cells, exploiting their in-built capacity for cofactor recycling. Even this approach suffers from problems, since cells are notoriously prone to poisoning by substrate/product toxicity, and side reactions may consume substrate or product. Redox biotransformations would be a much more attractive prospect if there were general methods to use isolated enzymes instead of whole cells. In this application, we propose to develop robust, cofactor-independent systems to deliver reducing power to redox enzymes in vitro using microfabricated electrochemical reactors which offer the prospect of a realistic approach to bioelectrocatalytic manufacturing. Our approach is to construct a generic platform technology based on a small number of well characterised catalytic frameworks that enables tailoring of reaction and substrate specificity to target reagents. The platform technology will provide a 'step change' in biocatalysis and allow us to develop a viable manufacturing process, independent of redox coenzymes, to exploit a wide range of novel and industrially relevant redox biotransformations.</gtr:technicalSummary><gtr:fund><gtr:end>2013-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2007-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1704122</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dr. Reddy's Laboratories</gtr:collaboratingOrganisation><gtr:country>India, Republic of</gtr:country><gtr:description>DrReddys</gtr:description><gtr:id>CCB095D0-998A-4925-8C0B-60F8201FE16E</gtr:id><gtr:impact>Developed ezymatic methods for production of fine chemicals.</gtr:impact><gtr:outcomeId>545912bb29da42.44292930-1</gtr:outcomeId><gtr:partnerContribution>Provided expertise and funded a CASE studentship</gtr:partnerContribution><gtr:piContribution>Provided expertise, research time and equipment.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>GSK</gtr:description><gtr:id>DBABB54E-AF50-4B08-8CDD-5AD4A565A847</gtr:id><gtr:impact>Synthetic biology methods for production of fine chemicals.</gtr:impact><gtr:outcomeId>545911e8dafa50.77931622-1</gtr:outcomeId><gtr:partnerContribution>Provided expertise and funding.</gtr:partnerContribution><gtr:piContribution>Provided expertise, research time and equipment.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Science Spectacular</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>45C9131D-A4C8-4E4A-B8AC-B968DAA0233E</gtr:id><gtr:impact>Members of research group presented exhibit on topics of enzymes and proteins. Event was well received by both students and their teachers and seemed to inspire interest in the subject.

No defined impacts realised to date</gtr:impact><gtr:outcomeId>545b8dd9a88fc8.06778672</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013,2014,2015,2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Several publications have emerged from the grant funded work documenting efficient laboratory based evolution of ene reductases (mainly PETNR) using our high throughput robotics platform. The work has established the general utility of ene reductase biocatalysts and their evolved variants as useful industrial biocatalysts for activated carbon-carbon double bond reductions. The technology has been transferred to industrial partners (GSK and Dr Reddy's) through licensing agreements.
 We have developed novel microreactors for reduction of unsaturated compounds based on microfluidic concepts that will facilitate these biotransformations in an industrial context. The designs enable enzyme/substrate recycling, efficient product removal in biphasic systems and avoid the use of expensive reducing coenzymes such as NADPH.</gtr:description><gtr:firstYearOfImpact>2007</gtr:firstYearOfImpact><gtr:id>783E1967-175D-4C4C-AB19-D4D488B36961</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>54538891840ad1.26887278</gtr:outcomeId><gtr:sector>Chemicals,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology,Other</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Method for preparing a mono-unsaturated alkene comprising contacting an aliphatic mono-unsaturated carboxylic acid with an Fdc1 polypeptide comprising an amino acid sequence with at least 21% sequence identity to SEQ ID NO: 1 and a Pad1 polypeptide comprising an amino acid sequence with at least 17% sequence identity to SEQ ID NO: 2.</gtr:description><gtr:grantRef>BB/E010717/1</gtr:grantRef><gtr:id>14C4B1CA-58CA-4A6B-8BFB-D38AF9C1E820</gtr:id><gtr:impact>.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>545265fbc9b089.23120005</gtr:outcomeId><gtr:patentId>US2013330795</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>METHODS FOR PREPARING A HYDROCARBON</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>We established routes to bioelectrocatalysis using our published microfluidic devices, identified novel biocatalysts with an extensive range of specificities, enantioselectivities and group chemistries. We were able to evolve many variants of ene reductases towards new target substrates.</gtr:description><gtr:id>0A802486-6CA3-4730-823D-E761BAC12B22</gtr:id><gtr:outcomeId>5451054c871966.06068879</gtr:outcomeId><gtr:sectors><gtr:sector>Chemicals,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology,Other</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Liquid handling robotics platform for directed evolution of enzyme activity.</gtr:description><gtr:id>3CE79315-F2CF-45B7-BC9F-3890180F91C6</gtr:id><gtr:impact>Publications</gtr:impact><gtr:outcomeId>545918e06c8d17.30389171</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Robot</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>AEDC2036-B1F6-4400-BC12-EB0CE97CE43A</gtr:id><gtr:title>ELDOR spectroscopy reveals that energy landscapes in human methionine synthase reductase are extensively remodelled following ligand and partner protein binding.</gtr:title><gtr:parentPublicationTitle>Chembiochem : a European journal of chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11dba2b10f350dff864cbff460ef1590"><gtr:id>11dba2b10f350dff864cbff460ef1590</gtr:id><gtr:otherNames>Rigby SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1439-4227</gtr:issn><gtr:outcomeId>544fd5bcb720c1.84592774</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08E98D30-8782-40C3-B161-E4996F5F6E68</gtr:id><gtr:title>A site-saturated mutagenesis study of pentaerythritol tetranitrate reductase reveals that residues 181 and 184 influence ligand binding, stereochemistry and reactivity.</gtr:title><gtr:parentPublicationTitle>Chembiochem : a European journal of chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/945abe6e38e453d4e73469f599c3a072"><gtr:id>945abe6e38e453d4e73469f599c3a072</gtr:id><gtr:otherNames>Toogood HS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1439-4227</gtr:issn><gtr:outcomeId>544fd5bc844c21.68128738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95E2481B-D86C-408D-99FF-8090784BFEF2</gtr:id><gtr:title>Flavins and Flavoproteins 2008, Proceedings of the 16th International Symposium on Flavins and Flavoproteins</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/945abe6e38e453d4e73469f599c3a072"><gtr:id>945abe6e38e453d4e73469f599c3a072</gtr:id><gtr:otherNames>Toogood HS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:isbn>9788477330172</gtr:isbn><gtr:outcomeId>5450d9e31576e4.33888139</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4B4525A-F017-4847-B971-C85AF7B33630</gtr:id><gtr:title>A surprising observation that oxygen can affect the product enantiopurity of an enzyme-catalysed reaction.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17ed104468c4b2e84c8ad9595fb15a0a"><gtr:id>17ed104468c4b2e84c8ad9595fb15a0a</gtr:id><gtr:otherNames>Fryszkowska A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>544fd5b81b5895.52475903</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>580AD29E-4A72-427F-9068-45C0E6116148</gtr:id><gtr:title>Structure-Based Insight into the Asymmetric Bioreduction of the C=C Double Bond of alpha,beta-Unsaturated Nitroalkenes by Pentaerythritol Tetranitrate Reductase.</gtr:title><gtr:parentPublicationTitle>Advanced synthesis &amp; catalysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/945abe6e38e453d4e73469f599c3a072"><gtr:id>945abe6e38e453d4e73469f599c3a072</gtr:id><gtr:otherNames>Toogood HS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1615-4150</gtr:issn><gtr:outcomeId>544fd5c4e900d2.91383194</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BE1196C-7068-4EE0-AAA2-FF00FC5563B9</gtr:id><gtr:title>Nanofibrillar Peptide hydrogels for the immobilization of biocatalysts for chemical transformations.</gtr:title><gtr:parentPublicationTitle>Macromolecular rapid communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f3256aae8d38b653b3329cef43a43a7"><gtr:id>1f3256aae8d38b653b3329cef43a43a7</gtr:id><gtr:otherNames>Hickling C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1022-1336</gtr:issn><gtr:outcomeId>544fd5b328fd01.80813139</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FF5274F-D6EE-4FA6-B643-66EDD7722386</gtr:id><gtr:title>Biocatalytic Asymmetric Alkene Reduction: Crystal Structure and Characterization of a Double Bond Reductase from.</gtr:title><gtr:parentPublicationTitle>ACS catalysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a50a004774bab748dfce3053f02e718"><gtr:id>8a50a004774bab748dfce3053f02e718</gtr:id><gtr:otherNames>Mansell DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>544fd5b77e1b28.78316369</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC57D366-B9BB-4AB4-9A73-D61175D1DF03</gtr:id><gtr:title>Alternative Hydride Sources for Ene-Reductases: Current Trends</gtr:title><gtr:parentPublicationTitle>ChemCatChem</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb3dcdb60e0f07422b8d071d7acece69"><gtr:id>bb3dcdb60e0f07422b8d071d7acece69</gtr:id><gtr:otherNames>Toogood H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>544fd5b44e2849.06673695</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DB903B6-6B71-4EF2-B4F7-C7FA3BBA8EB9</gtr:id><gtr:title>Dynamics driving function: new insights from electron transferring flavoproteins and partner complexes.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/945abe6e38e453d4e73469f599c3a072"><gtr:id>945abe6e38e453d4e73469f599c3a072</gtr:id><gtr:otherNames>Toogood HS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>544fd5c9505e76.06794460</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C01F0DE7-8024-482C-98FD-97A4CA089DBE</gtr:id><gtr:title>New developments in 'ene'-reductase catalysed biological hydrogenations.</gtr:title><gtr:parentPublicationTitle>Current opinion in chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/945abe6e38e453d4e73469f599c3a072"><gtr:id>945abe6e38e453d4e73469f599c3a072</gtr:id><gtr:otherNames>Toogood HS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1367-5931</gtr:issn><gtr:outcomeId>544fd5b35dc211.02204045</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E705B7BE-4153-45F8-9D20-EF78356CE31E</gtr:id><gtr:title>Mechanism of coenzyme binding to human methionine synthase reductase revealed through the crystal structure of the FNR-like module and isothermal titration calorimetry.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d40fb07c552a1407f59a24fc13b7b3d1"><gtr:id>d40fb07c552a1407f59a24fc13b7b3d1</gtr:id><gtr:otherNames>Wolthers KR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn><gtr:outcomeId>544fd5c9b64f59.27055383</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81FF1B02-912F-49A2-ACBF-287281064998</gtr:id><gtr:title>Focused directed evolution of pentaerythritol tetranitrate reductase by using automated anaerobic kinetic screening of site-saturated libraries.</gtr:title><gtr:parentPublicationTitle>Chembiochem : a European journal of chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f45bcf355bcd161524c0b93928dae98"><gtr:id>9f45bcf355bcd161524c0b93928dae98</gtr:id><gtr:otherNames>Hulley ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1439-4227</gtr:issn><gtr:outcomeId>544fd5bd954f12.84073871</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B079B5D2-1C15-472A-B72F-C71FD64ECAA9</gtr:id><gtr:title>Enzymes - Nature's catalytic machines</gtr:title><gtr:parentPublicationTitle>Biological Sciences Review</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e003e258e15bed700fb2ea3c25f07d0"><gtr:id>0e003e258e15bed700fb2ea3c25f07d0</gtr:id><gtr:otherNames>Heyes DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>544fd78d4238a8.16491212</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6361E739-EBEB-4899-9646-0B7A91823358</gtr:id><gtr:title>Biocatalytic Reductions and Chemical Versatility of the Old Yellow Enzyme Family of Flavoprotein Oxidoreductases</gtr:title><gtr:parentPublicationTitle>ChemCatChem</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb3dcdb60e0f07422b8d071d7acece69"><gtr:id>bb3dcdb60e0f07422b8d071d7acece69</gtr:id><gtr:otherNames>Toogood H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>544fd5be051a20.07434039</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28C5684D-068F-4257-A8F6-D5C9893EA35F</gtr:id><gtr:title>Comprehensive Chirality</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb3dcdb60e0f07422b8d071d7acece69"><gtr:id>bb3dcdb60e0f07422b8d071d7acece69</gtr:id><gtr:otherNames>Toogood H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:isbn>9780080951683</gtr:isbn><gtr:outcomeId>5450d7a54d5e67.32864137</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>071C6C33-D48D-4365-9A8A-ABEE9635784B</gtr:id><gtr:title>Protein Engineering Handbook Volume 3</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/945abe6e38e453d4e73469f599c3a072"><gtr:id>945abe6e38e453d4e73469f599c3a072</gtr:id><gtr:otherNames>Toogood HS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:isbn>978-3-527-33123-9</gtr:isbn><gtr:outcomeId>5450d698d611d4.02292972</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E622742-5FE5-4008-8ADD-F10ABD60DC6E</gtr:id><gtr:title>Enzyme engineering toolbox - a 'catalyst' for change</gtr:title><gtr:parentPublicationTitle>Catalysis Science &amp; Technology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb3dcdb60e0f07422b8d071d7acece69"><gtr:id>bb3dcdb60e0f07422b8d071d7acece69</gtr:id><gtr:otherNames>Toogood H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>544fd5b2827730.34896821</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F79FBAF-59A8-43B9-9E48-614FF393522A</gtr:id><gtr:title>Electro-enzymatic viologen-mediated substrate reduction using pentaerythritol tetranitrate reductase and a parallel, segmented fluid flow system</gtr:title><gtr:parentPublicationTitle>Catalysis Science &amp; Technology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a52b69a9c493b432e47848255c855c80"><gtr:id>a52b69a9c493b432e47848255c855c80</gtr:id><gtr:otherNames>Fisher K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>544fd5b71e9b24.24476692</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>301001B7-889D-41EE-A393-FF8E37B98302</gtr:id><gtr:title>Continuous two-phase flow miniaturised bioreactor for monitoring anaerobic biocatalysis by pentaerythritol tetranitrate reductase.</gtr:title><gtr:parentPublicationTitle>Lab on a chip</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e529b5c054fabeb7fd54e304b91ba1f1"><gtr:id>e529b5c054fabeb7fd54e304b91ba1f1</gtr:id><gtr:otherNames>Mohr S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1473-0189</gtr:issn><gtr:outcomeId>544fd5be626d40.22271066</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85D8288E-6D75-4B1F-8CBB-3D4A073115D5</gtr:id><gtr:title>Biocatalysis with thermostable enzymes: structure and properties of a thermophilic 'ene'-reductase related to old yellow enzyme.</gtr:title><gtr:parentPublicationTitle>Chembiochem : a European journal of chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0b9aa00c6ea382303e3f232b29bc66b"><gtr:id>b0b9aa00c6ea382303e3f232b29bc66b</gtr:id><gtr:otherNames>Adalbj?rnsson BV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1439-4227</gtr:issn><gtr:outcomeId>544fd5bfee7d40.86292563</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFF25439-97A0-4DF2-91A5-4BACBF59DED2</gtr:id><gtr:title>Asymmetric Reduction of Activated Alkenes by Pentaerythritol Tetranitrate Reductase: Specificity and Control of Stereochemical Outcome by Reaction Optimisation</gtr:title><gtr:parentPublicationTitle>Advanced Synthesis &amp; Catalysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17ed104468c4b2e84c8ad9595fb15a0a"><gtr:id>17ed104468c4b2e84c8ad9595fb15a0a</gtr:id><gtr:otherNames>Fryszkowska A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>544fd5c02a12d7.22013966</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8418C5E6-7ED8-4FA6-920D-A57EA430D78F</gtr:id><gtr:title>Reduction of aliphatic nitroesters and N-nitramines by Enterobacter cloacae PB2 pentaerythritol tetranitrate reductase: quantitative structure-activity relationships.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b347313d7c3980f4bfd9b9e2fd0cf5a1"><gtr:id>b347313d7c3980f4bfd9b9e2fd0cf5a1</gtr:id><gtr:otherNames>Nivinskas H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>544fd5c55ddbc0.41722580</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C250E0A-CDB2-4436-8C95-31447BAEA65B</gtr:id><gtr:title>Active site modifications in pentaerythritol tetranitrate reductase can lead to improved product enantiopurity, decreased by-product formation and altered stereochemical outcome in reactions with &amp;Icirc;&amp;plusmn;,&amp;Icirc;&amp;sup2;-unsaturated nitroolefins</gtr:title><gtr:parentPublicationTitle>Catalysis Science &amp; Technology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17ed104468c4b2e84c8ad9595fb15a0a"><gtr:id>17ed104468c4b2e84c8ad9595fb15a0a</gtr:id><gtr:otherNames>Fryszkowska A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>544fd5bc49f511.26044312</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/E010717/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>